Astellas PharmaMEX:4503N 78 FCF Yield % is 12.18 as of Jun. 25, 2026, which is 105% above its 10-year median of 5.95. GuruFocus rates MEX:4503N with a GF Score™ of 78/100 and a GF Value™ of MXN246.87 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Astellas Pharma ranks better than 90.85% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Astellas Pharma FCF Yield % Related Terms
Astellas Pharma FCF Yield % Historical Data
* Premium members only.
The historical data trend for Astellas Pharma's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:4503N vs LLY, JNJ, ABBV: FCF Yield % Comparison
For the Drug Manufacturers - General subindustry, Astellas Pharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astellas Pharma (MEX:4503N) has a FCF Yield % of 12.18 as of Jun. 25, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Astellas Pharma and its competitors. This is 105% above median its historical median of 5.95. Over the past decade, Astellas Pharma's FCF Yield % has ranged from 2.50 to 12.46. According to the industry distribution chart, Astellas Pharma ranks #92 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 9.2%.
Is Astellas Pharma's FCF Yield % too high?
Astellas Pharma's current FCF Yield % of 12.18 is 105% above median its 10-year median of 5.95. Over the past 10 years, this metric has ranged from a low of 2.50 to a high of 12.46. The Drug Manufacturers industry median FCF Yield % is 0.67. Astellas Pharma's value of 12.18 is 1717.9% above this industry median. Based on the distribution chart, Astellas Pharma ranks #92 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Astellas Pharma has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's FCF Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #92 out of 1005 companies for FCF Yield %. This places Astellas Pharma in the top 9% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.67. Astellas Pharma's value of 12.18 is 1717.9% above this benchmark. Historically, Astellas Pharma's own FCF Yield % has ranged from 2.50 to 12.46 over the past decade. While the company's 10-year median is 5.95 vs. the industry median of 0.67, Astellas Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current FCF Yield % of 12.18 is 1717.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Astellas Pharma and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current FCF Yield % is 12.18, which is 105% above median its own 10-year median of 5.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (MEX:4503N) is currently considered Fairly Valued. The stock's GF Value™ is MXN246.87, compared to a current price of MXN253.57 — trading 2.7% above its estimated fair value. The current FCF Yield % is 12.18, which is 105% above median its 10-year median of 5.95 and 1717.9% above the Drug Manufacturers industry median of 0.67. Astellas Pharma's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Astellas Pharma (MEX:4503N), the current FCF Yield % is 12.18 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (MEX:4503N) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be overvalued.
The current stock price of MXN253.57 is trading 2.7% above its estimated GF Value™ of MXN246.87.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for MEX:4503N:
FCF Yield %: 12.18 (105% above median its 10-year median of 5.95)
GF Value™: MXN246.87 vs. price of MXN253.57 (2.7% above fair value)
Industry Position: 1717.9% above the Drug Manufacturers median (#92 of 1005)
No single metric tells the full story. See the MEX:4503N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
78GF Score
Get the complete analysis for MEX:4503N
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:4503N has been successfully added to your 
